Q1: 2026-05-13 Earnings Summary
EPS of -$0.18 beats by $0.00
| Revenue of $0.00 misses by $1,820.00
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call May 13, 2026 5:00 PM EDT
Company Participants
Christine Cassiano – Executive VP, Chief Corporate Affairs & Brand Strategy Officer
David Chang – Co-Founder, President, CEO & Director
Zachary Roberts – Executive VP of Research & Development and Chief Medical Officer
Geoffrey Parker – Executive VP & CFO
Conference Call Participants
Michael Yee – UBS Investment Bank, Research Division
Tyler Van Buren – TD Cowen, Research Division
Biren Amin – Piper Sandler & Co., Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Matthew Phipps – William Blair & Company L.L.C., Research Division
Jack Allen – Robert W. Baird & Co. Incorporated, Research Division
John Newman – Canaccord Genuity Corp., Research Division
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Presentation
Operator
Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] Please be aware that today’s conference call is being recorded.
I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer.
Ms. Cassiano, please go ahead.
Christine Cassiano
Executive VP, Chief Corporate Affairs & Brand Strategy Officer
Thank you, operator, and welcome, everyone, to Allogene’s conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the first quarter of 2026. This press release and today’s webcast are available on our website.
Following our prepared remarks, we will host a Q&A session and we will aim to keep the call to under an hour. I’m joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.
